November 11, 2026

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

Ref: Scrip Code: 543322

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Name: ALIVUS

Dear Sirs,

Sub: Intimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations")

In compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with corresponding circulars and notifications issued thereunder, it is hereby informed to you that Company executed a Shareholders' Agreement ("SHA") with IQGEN-X Pharma Private Limited ("IQGEN-X") and Continuing Existing Shareholders of ('CES') IQGEN-X, to record their mutual understanding with respect to, amongst others, *inter se* rights and obligations by virtue of their shareholding and certain other matters as mentioned in the SHA.

The details of SHA, as required under Regulation 30 of the Listing Regulations read with Schedule III thereto and the applicable SEBI Master Circular are enclosed as **Annexure A**.

You are requested to kindly takes note of the same.

This is for your information and records

Thanking You,

Your Sincerely,

For Alivus Life Sciences Limited
(formerly Glenmark Life Sciences Limited)

RUDALF JOSEPH CORRIEA
Digitally signed by RUDALF JOSEPH CORRIEA
Date: 2026.11.11 16:45:29 +05'30'

Rudalf Corriea
Company Secretary & Compliance Officer
Encl: As above

Annexure A

The details as required in terms of Regulation 30 and Regulation 5 and 5A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026 are as under: -

Sr. No.	Particulars	Details
1.	Name(s) of parties with whom the agreement is entered	Agreement has entered by and between Alivus Life Sciences Limited ("Company"), Dr. Mandar Kodgule & Dr. Yogita Kodgule (collectively 'Continuing Existing Shareholders' ('CES') and IQGEN-X Pharma Private Limited.
2.	Purpose of entering into the agreement	To record Shareholders mutual understanding with respect to, amongst others, *inter se* rights and obligations by virtue of their shareholding and certain other matters as mentioned in the SHA.
3.	Shareholding, if any, in the entity with whom the agreement is executed	The Company had entered into share purchase agreement to acquire 76% stake in IQGEN-X Pharma Private Limited.
4.	Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.	• The Company has an option to Buy the remaining 24% of CES shareholding at the end of 5 years from the date of closing of this transaction at a pre agreed Benchmark price defined in the SHA • Board Composition: 3 Directors (2 from the Company, 1 from CES). • No transfer of shares except as permitted by the Agreement
5.	extent and the nature of impact on management or control of the listed entity	No impact on management or control of the listed entity
6.	details and quantification of the restriction or liability imposed upon the listed entity	Not Applicable
7.	Whether, the said parties are related to promoter/promoter group/ group companies in any	No

	manner. If yes, nature of relationship	
8..	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”;	No. However, the Company has entered into share purchase agreement to acquire 76% stake in IQGEN-X Pharma Private Limited.
9.	In case of issuance of shares to the parties, details of issue price, class of shares issued	Not Applicable
10.	Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.	The Company has right to appoint majority Directors in IQGEN-X. No potential conflict of interest arising out of this SHA.
11.	in case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): a) name of parties to the agreement; b) nature of the agreement; c) date of execution of the agreement; d) details of amendment and impact thereof or reasons of termination and impact thereof.	Not Applicable